| Serial Number | 79209645 |
| Word Mark | CRESCENDO BIOLOGICS |
| Filing Date | Friday, October 21, 2016 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, June 12, 2018 |
| Registration Number | 5488713 |
| Registration Date | Tuesday, June 12, 2018 |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, March 27, 2018 |
| Goods and Services | Treatment and transformation of materials for others, namely the custom manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing services in the field of chemicals, biologicals, antibodies and antibody fragments; services for the custom manufacture of medical therapies using antibodies and antibody fragments |
| Description of Mark | The mark consists of a design of three circles each having U-shaped cut-outs. The three circles are centered above the stylized wording "Crescendo" directly above the stylised wording "biologics". |
| Goods and Services | Pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; veterinary preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; therapeutic preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes, namely, therapeutic pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibodies, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; monoclonal antibody therapies for therapeutic purposes, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for medical and veterinary diagnostics; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for use in the discovery, preclinical and clinical development of therapeutic products; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for use in the manufacture of therapeutic products |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| Goods and Services | Chemicals used in industry and science; chemicals for laboratory research purposes, namely, chemical tests kits for in vitro testing; antibodies and antibody fragments for scientific and laboratory use in the nature of biochemical, namely, monoclonal antibodies for in vitro scientific or research use; biochemical, namely, monoclonal antibodies and antibody fragments for scientific and laboratory use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for scientific and laboratory in vitro diagnostic use; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical and clinical development of therapeutic products |
| NOT AVAILABLE | "BIOLOGICS" |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, June 12, 2017 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, June 12, 2017 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, June 12, 2017 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Crescendo Biologics Limited |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Party Name | Crescendo Biologics Limited |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Party Name | Crescendo Biologics Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Event Date | Event Description |
| Thursday, June 8, 2017 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Monday, June 12, 2017 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, June 12, 2017 | ASSIGNED TO EXAMINER |
| Wednesday, June 14, 2017 | NON-FINAL ACTION WRITTEN |
| Thursday, June 15, 2017 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Friday, June 16, 2017 | APPLICATION FILING RECEIPT MAILED |
| Friday, June 23, 2017 | REFUSAL PROCESSED BY MPU |
| Friday, June 23, 2017 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Friday, July 14, 2017 | REFUSAL PROCESSED BY IB |
| Thursday, December 7, 2017 | NEW REPRESENTATIVE AT IB RECEIVED |
| Tuesday, December 19, 2017 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, December 19, 2017 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, December 20, 2017 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, January 11, 2018 | FINAL REFUSAL WRITTEN |
| Friday, January 12, 2018 | FINAL REFUSAL MAILED |
| Thursday, February 1, 2018 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Thursday, February 1, 2018 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Wednesday, February 14, 2018 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Wednesday, February 14, 2018 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, February 14, 2018 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, February 16, 2018 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, March 7, 2018 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, March 7, 2018 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, March 7, 2018 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Saturday, March 24, 2018 | NOTIFICATION PROCESSED BY IB |
| Tuesday, March 27, 2018 | PUBLISHED FOR OPPOSITION |
| Tuesday, March 27, 2018 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, June 12, 2018 | REGISTERED-PRINCIPAL REGISTER |
| Wednesday, September 12, 2018 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Tuesday, September 18, 2018 | FINAL DISPOSITION PROCESSED |
| Tuesday, September 18, 2018 | FINAL DISPOSITION NOTICE SENT TO IB |
| Saturday, October 6, 2018 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Monday, June 12, 2023 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED |
| Saturday, August 19, 2023 | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED |
| Friday, October 27, 2023 | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED |
| Friday, November 8, 2024 | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED |